{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:46:37Z","timestamp":1771332397258,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:p>Hepatocellular carcinoma (HCC) <jats:italic toggle=\"yes\">with<\/jats:italic> portal vein tumor thrombus is considered an advanced stage disease. Non-surgical local and systemic therapies are the only treatment options available. To analyze the survival and toxicity outcomes of systemic treatment concurrent with yttrium-90 transarterial radioembolization in HCC with liver-limited disease and portal vein involvement with Child\u2013Pugh B liver reserve. The medical records of 22 patients who underwent yttrium-90 transarterial radioembolization concomitant with capecitabine chemotherapy as first-line treatment between 2014 and 2019 were retrospectively reviewed. Twenty-two patients were included in the study. Grade 3 to 4 side effects were evaluated, and hepatic encephalopathy developed in 1 patient after yttrium-90 transarterial radioembolization. In the fourth month of radiological evaluation, 11 patients had a partial response (50%), 5 patients had stable disease (22.7%), and 6 patients (27.3%) developed progressive disease. The median survival time was 21 months. Combined treatment with yttrium-90 transarterial radioembolization and capecitabine may be an effective and safe treatment option. Treatment was associated with a median overall survival of 21 months and a disease control rate of 72.7% at 4 months in patients with inoperable HCC.<\/jats:p>","DOI":"10.1097\/md.0000000000034674","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T21:04:38Z","timestamp":1693602278000},"page":"e34674","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement"],"prefix":"10.1097","volume":"102","author":[{"given":"Nur","family":"\u015eener","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Memorial Ata\u015fehir Hospital, \u0130stanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-687X","authenticated-orcid":false,"given":"Abdullah","family":"Yakupo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Memorial \u015ei\u015fli Hospital, \u0130stanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4254\/wjh.v7.i9.1157","article-title":"Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome.","volume":"7","author":"Bodzin","year":"2015","journal-title":"World J Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.3748\/wjg.v21.i12.3462","article-title":"Management of hepatocellular carcinoma with portal vein thrombosis.","volume":"21","author":"Quirk","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.3390\/cancers13194876","article-title":"The role of cytokines in the different stages of hepatocellular carcinoma.","volume":"13","author":"Rico Montanari","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.3748\/wjg.v22.i32.7289","article-title":"Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016.","volume":"22","author":"Chan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.12998\/wjcc.v10.i21.7275","article-title":"Clinical values of Barcelona Clinic Liver Cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization.","volume":"10","author":"Lee","year":"2022","journal-title":"World J Clin Cases"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies.","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2019","journal-title":"Lancet Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"33911","DOI":"10.18632\/oncotarget.15411","article-title":"Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline.","volume":"38","author":"Gordan","year":"2020","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3748\/wjg.v22.i1.407","article-title":"Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review.","volume":"22","author":"Han","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ueg2.12286","article-title":"New concepts in the treatment of hepatocellular carcinoma.","volume":"10","author":"Sidali","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00270-005-0171-4","article-title":"Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.","volume":"29","author":"Sato","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/COC.0b013e3181ec61bb","article-title":"General selection criteria of patients for radioembolization of liver tumors: an international working group report.","volume":"34","author":"Coldwell","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.3390\/cancers14153710","article-title":"Efficacy of transarterial chemoembolization combined with molecular targeted agents for unresectable hepatocellular carcinoma: a network meta-analysis.","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jceh.2021.12.009","article-title":"Transarterial Chemoembolization (TACE) combined with sorafenib versus TACE in patients with BCLC Stage C hepatocellular carcinoma \u2013 a retrospective study.","volume":"12","author":"Patidar","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/tcmj.tcmj_84_21","article-title":"Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: a real-world propensity score-matched study.","volume":"34","author":"Peng","year":"2021","journal-title":"Tzu Chi Med J"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40261-015-0333-3","article-title":"Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate\/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.","volume":"35","author":"Ohki","year":"2015","journal-title":"Clin Drug Investig"},{"key":"R20-20250504","first-page":"1066","article-title":"Sorafenib combined with chemoembolization for locally advanced hepatocellular carcinoma with macroscopic vascular invasion: a propensity score analysis.","volume":"11","author":"Kim","year":"2021","journal-title":"Life (Basel)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial.","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial.","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer.","volume":"34","author":"van Hazel","year":"2016","journal-title":"J Clin Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","article-title":"Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.","volume":"50","author":"Salem","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3390\/cancers14102357","article-title":"Therapeutic management of advanced hepatocellular carcinoma: an updated review.","volume":"14","author":"Falette Puisieux","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma.","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0168-8278(18)30424-0","article-title":"The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the Soramic trial alliative cohort.","volume":"68","author":"Ricke","year":"2018","journal-title":"J Hepatol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bjc.2014.344","article-title":"Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.","volume":"111","author":"Cohen","year":"2014","journal-title":"Br J Cancer"},{"key":"R32-20250504","first-page":"1","article-title":"Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma.","volume":"3","author":"Mahvash","year":"2016","journal-title":"J Hepatocell Carcinoma"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fonc.2013.00323","article-title":"Yttrium-90 radioembolization in patients with hepatocellular carcinoma who have previously received sorafenib.","volume":"3","author":"Rana","year":"2013","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:11:17Z","timestamp":1746324677000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":32,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034674","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}